Mustang Bio (MBIO) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mustang Bio is the larger company by market cap ($3.2 million vs $2.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | VIVS |
|---|---|---|
| Share price | $0.417 | $0.1772 |
| Market cap | $3.16M | $2.94M |
| 1-day change | -7.37% | -7.47% |
| EPS (TTM) | $-0.44 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.81 | $3.41 |
| 52-week low | $0.41 | $0.17 |
| Distance from 52-week high | -76.96% | -94.80% |
| Average volume | 29.38K | 5.85M |
| Shares outstanding | 6.73M | 16.59M |
| Employees | 4 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Healthcare · Biotechnology · 4 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Healthcare · Biotechnology · 15 employees
MBIO vs VIVS FAQ
Which is bigger, Mustang Bio or VivoSim Labs?
Mustang Bio (MBIO) is larger, with a market capitalization of $3.16M compared with $2.94M for VivoSim Labs (VIVS).
Are Mustang Bio and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.